^
    Back
    Association details:
    Biomarker:MUC1 expression + EGFR expression
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:M1231 (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate, MUC1-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    M1231 in Participants With Solid Tumors

    Excerpt:
    ...- Participants with solid tumors expressing or likely to expressing EGFR and MUC1, including but...
    Trial ID:
    NCT04695847
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression

    Published date:
    06/15/2022
    Excerpt:
    Strong antitumor activity with complete regression was observed in NSCLC and ESCC PDX models following a single treatment of M1231. M1231 antitumor activity was associated with high target expression in NSCLC PDX models and was observed across a range of target expression levels in ESCC models. In summary, efficient payload delivery to tumor cells and strong antitumor activity of M1231 indicate that M1231 may have the potential to deliver an efficacy benefit to patients with tumors co-expressing MUC1 and EGFR.
    DOI:
    https://doi.org/10.1158/1538-7445.AM2022-5284